Blog
Alemtuzumab: Mechanism, Applications, and Biosimilar Advancements
Alemtuzumab is a monoclonal antibody targeting CD52, a glycoprotein highly expressed on mature lymphocytes. By binding CD52, Alemtuzumab induces immune-mediated depletion of lymphocytes,
…
13th Jan 2025